2021
Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
Llanos-Chea F, Jelani QU, Trejo-Paredes C, Curtis JP, Parzynski CS, Huang J, Faridi KF, Turner J, Smolderen KG, Mena-Hurtado C. Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia. Journal Of The American College Of Cardiology 2021, 77: 1374-1375. PMID: 33706882, DOI: 10.1016/j.jacc.2020.12.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCohort StudiesEndovascular ProceduresFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIschemiaMaleMiddle AgedPeripheral Arterial DiseasePlatelet Aggregation Inhibitors
2014
Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008
Schneider PM, Pellegrini CN, Wang Y, Fein AS, Reynolds MR, Curtis JP, Masoudi FA, Varosy PD. Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. The American Journal Of Cardiology 2014, 113: 2052-2056. PMID: 24793671, PMCID: PMC4346333, DOI: 10.1016/j.amjcard.2014.03.049.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCardiac Resynchronization TherapyCombined Modality TherapyDeath, Sudden, CardiacDefibrillators, ImplantableFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedPractice Guidelines as TopicPrevalenceRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesVentricular Dysfunction, LeftConceptsGuideline-directed medical therapyCardiac resynchronization therapyImplantable Cardioverter-Defibrillator RegistryAngiotensin II receptor inhibitorΒ-blockersMedical therapyClass IReceptor inhibitorsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryCardiac resynchronization therapy defibrillator implantationLeft ventricular systolic dysfunctionSevere heart failure symptomsAngiotensin-converting enzyme inhibitorNational Cardiovascular Data RegistryClass I indicationsCRT-D implantationHeart failure symptomsVentricular systolic dysfunctionProportion of patientsSelection of patientsReal-world patientsAngiotensin-converting enzymePrevalence of guidelinesContemporaneous guidelinesQuality improvement targets
2011
Optimal Medical Therapy Use Among Patients Receiving Implantable Cardioverter/Defibrillators: Insights From the National Cardiovascular Data Registry
Miller AL, Wang Y, Curtis J, Masoudi FA, Buxton AE, Wang TY. Optimal Medical Therapy Use Among Patients Receiving Implantable Cardioverter/Defibrillators: Insights From the National Cardiovascular Data Registry. JAMA Internal Medicine 2011, 172: 64-67. PMID: 22082711, DOI: 10.1001/archinternmed.2011.466.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsDefibrillators, ImplantableGuideline AdherenceHeart DiseasesHumansRegistries
2006
Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project
Rathore SS, Masoudi FA, Wang Y, Curtis JP, Foody JM, Havranek EP, Krumholz HM. Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project. American Heart Journal 2006, 152: 371-378. PMID: 16875925, PMCID: PMC2790269, DOI: 10.1016/j.ahj.2005.12.002.Peer-Reviewed Original ResearchConceptsLeft ventricular systolic function assessmentHigh SES patientsVentricular systolic function assessmentHeart failureSES patientsSystolic function assessmentYear of dischargeQuality of careSocioeconomic statusMultivariable adjustmentFunction assessmentEnzyme inhibitorsNational Heart Failure ProjectHeart Failure ProjectPrescription of angiotensinLow SES patientsPatients' socioeconomic statusAssociation of SESYear of admissionMedical record dataHierarchical logistic regression modelsLow socioeconomic statusLogistic regression modelsPatient sElderly patients
2004
National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2004, 110: 724-731. PMID: 15289383, DOI: 10.1161/01.cir.0000138934.28340.ed.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCohort StudiesComorbidityCreatinineDrug PrescriptionsDrug UtilizationFemaleHeart FailureHumansMalePatient DischargeStroke VolumeUnited StatesVentricular Dysfunction, LeftConceptsACE inhibitor prescriptionAngiotensin receptor blockersVentricular systolic dysfunctionHeart failureACE inhibitorsInhibitor prescriptionSystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionAngiotensin converting enzyme (ACE) inhibitorsSerum creatinine levelsACE inhibitor useCreatinine levelsHospital factorsInhibitor useReceptor blockersSerum creatininePatient genderClinical trialsTherapeutic substitutionLower riskEnzyme inhibitorsLower mortalityPatientsSecondary analysisModulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke
Sokol SI, Portnay EL, Curtis JP, Nelson MA, Hebert PR, Setaro JF, Foody JM. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004, 63: 208-213. PMID: 15277610, DOI: 10.1212/01.wnl.0000130360.21618.d0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAnimalsBrainChronic DiseaseDouble-Blind MethodDrug Evaluation, PreclinicalEndothelium, VascularFibrinolysisHemostasisHumansInflammationMiddle AgedNerve RegenerationRandomized Controlled Trials as TopicRatsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Renin-Angiotensin SystemSecondary PreventionStrokeTreatment OutcomeConceptsRenin angiotensin aldosterone systemRAAS modulationRecurrent strokeAldosterone systemCerebrovascular eventsStroke preventionSecondary preventionACE inhibitorsCerebrovascular diseaseAngiotensin II type 1 receptor blocker therapiesBlood pressure-independent mechanismsMajor public health concernReceptor blocker therapyRecurrent cerebrovascular eventsRecurrent stroke preventionAngiotensin aldosterone systemBlood pressure reductionSecondary stroke preventionRecurrent cardiac eventsPressure-independent mechanismsVascular structural changesOngoing clinical trialsNew treatment strategiesPublic health concernBlocker therapy